The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to ifinatamab deruxtecan (I-DXd) for the treatment of adults with extensive-stage small cell lung cancer (ES-SCLC ...

An analysis of more than 13 million EHR notes revealed evidence suggesting racial bias in how doctors document patient credibility.